InvestorsHub Logo
Followers 86
Posts 12714
Boards Moderated 0
Alias Born 10/12/2010

Re: cjgaddy post# 280961

Saturday, 12/10/2016 5:22:31 PM

Saturday, December 10, 2016 5:22:31 PM

Post# of 345746
Excellent post CJ! and it is unbelievable that Peregrine can be this close to a break-even quarter. From here on out everything increases anyhow with full capacity of Avid II and very shortly Avid III as well. Every biotech out there would love to have the cash that Avid provides... and Steve King was behind starting Avid I in house and now, that move is turning out to be priceless.

I don't see other biotechs out there being as innovative as this and I wonder why...... maybe because other small biotech BOD's are only thinking about the short term and not the longterm.


"Bavituximab is a first-in-class phosphatidylserine (PS)-targeting monoclonal antibody that is the cornerstone of a broad clinical
pipeline."
-- Big Pharmas nightmare... unless they are fortunate enough to have The Bavi Edge!

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent CDMO News